Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6

doi:10.5306/wjco.v16.i11.111627

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

(36)

(48)

(0)

(18)

(945)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Clin Oncol. Nov 24, 2025; 16(11): 111627
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111627

Full Size Figure Download Figure

Figure 3 Prognosis and diagnostic value analysis of ectonucleoside triphosphate diphosphohydrolase 6 in various cancers. A-D: The univariate Cox regression analysis of overall survival, disease-specific survival, disease-free interval, and progression-free interval; E-I: The results of Kaplan-Meier curves analysis of overall survival in liver hepatocellular carcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, thymoma, and rectal adenocarcinoma; J-N: The results of the Kaplan-Meier curves analysis of progression-free interval in cervical squamous cell carcinoma and endocervical adenocarcinoma, diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, lung squamous cell carcinoma, and stomach adenocarcinoma; O-Q: The results of the Kaplan-Meier curves analysis of disease-specific survival in lung squamous cell carcinoma, kidney renal papillary cell carcinoma, and kidney renal clear cell carcinoma. ENTPD6: Ectonucleoside triphosphate diphosphohydrolase 6; OS: Overall survival; DSS: Disease-specific survival; DFI: Disease-free interval; PFI: Progression-free interval; LIHC: Liver hepatocellular carcinoma; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; THYM: Thymoma; READ: Rectal adenocarcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; DLBC: Diffuse large B-cell lymphoma; HNSC: Head and neck squamous cell carcinoma; LUSC: Lung squamous cell carcinoma; STAD: Stomach adenocarcinoma.

Citation: Wang G, Liu T, Zhang JX, Li YR, Zhu WJ, Wang JL, Dong WW, Zhang YY, Li YM, Yang LX, He LX, He WT. Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6. World J Clin Oncol 2025; 16(11): 111627
URL: https://www.wjgnet.com/2218-4333/full/v16/i11/111627.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i11.111627

Wang G, Liu T, Zhang JX, Li YR, Zhu WJ, Wang JL, Dong WW, Zhang YY, Li YM, Yang LX, He LX, He WT. Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6. World J Clin Oncol 2025; 16(11): 111627 [PMID: 41355910 DOI: 10.5306/wjco.v16.i11.111627]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.